Core Insights - The article highlights four overlooked safe haven stocks that are appealing to investors seeking stability amid market volatility, particularly with the CBOE Volatility Index (VIX) rising significantly [1] Group 1: Stock Summaries - **Envela (ELA)**: This Texas-based luxury goods reseller has seen a 110% gain over the past year, though it is down 2.99% year-to-date. It has a low beta of 0.281, indicating low volatility, and trades at a trailing P/E of 33x with 74.2% insider ownership [1] - **York Water (YORW)**: This company has paid uninterrupted dividends for over 200 years and recently raised its quarterly dividend to $0.228 per share, yielding approximately 2.72%. Full-year 2025 revenue grew 3.37% to $77.49 million, but earnings per share (EPS) slightly decreased to $1.39 [1] - **MGE Energy (MGEE)**: The utility company reported a full-year EPS of $3.72, beating estimates by 2.01%, and revenue of $743.65 million, exceeding estimates by 3.36%. The company has a beta of 0.782 and has consistently raised its dividend, now at $0.475 per share [1] - **Enhabit (EHAB)**: This home health operator is set to be acquired at $13.80 per share in a $1.10 billion deal. The stock has surged 48.16% year-to-date and 60.14% over the past year, with significant operational improvements noted in its hospice segment [1] Group 2: Market Context - The elevated volatility in the market, indicated by the VIX at 25.50 and up 34.9% over the past month, is driving investors toward stocks that offer stability and predictable income [1] - The 10-year Treasury yield has decreased to 4.13%, making dividend-paying equities more attractive compared to fixed-income investments [1]

PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Kaskela Law LLC has launched an investigation into the fairness of the recently announced proposed buyout of Enhabit, Inc. (NYSE: EHAB) shareholders to determine whether the $13.80 per share buyout price undervalues the company’s shares.  Click here to request additional information: https://kaskelalaw.com/case/enhabit/ On February 23, 2026, Enhabit announced that it had agreed to be acquired by private equity firm Kinderhook Industries at a price of $13.80 p ...

Company Operations and Growth - As of December 31, 2025, the company operated 249 home health and 117 hospice locations across 34 states, achieving a total net service revenue of $1.06 billion, with home health contributing $813.8 million (76.8%) and hospice $246.2 million (23.2%)[25] - The average daily census for the Home Health segment was 41,786 patients, while the Hospice segment had an average daily census of 3,985 patients for the year ended December 31, 2025[25] - The company has deployed over $798 million in capital on 42 home health and hospice acquisitions since 2015, and opened 54 new locations across 23 states during the same period[37] - The company’s growth strategy includes organic growth through existing operations, opening new locations, and increasing Payer Innovation contracts, alongside pursuing strategic acquisitions[48] - Since 2015, the company has opened 54 de novo locations, with expected costs ranging from approximately $250,000 to $350,000 per location, achieving profitability within 18 to 24 months[50] - In 2026, the company anticipates opening three to six home health and nine to twelve hospice de novos, leveraging existing leadership and brand recognition[51] - The company operates 249 home health agencies in 33 states and 117 hospice provider locations in 25 states as of December 31, 2025[62][65] Financial Performance and Revenue Sources - For the year ended December 31, 2025, revenues from Medicare and Medicare Advantage represented 89.7% of total net service revenue, with Medicare revenue at 65.8% and Medicare Advantage at 23.9%[78] - As of December 31, 2025, 57% of the company's non-Medicare revenue was derived from Payer Innovation contracts, reflecting successful negotiations with Medicare Advantage payers[46] - The company plans to invest $25 to $50 million in strategic acquisitions in 2026, focusing on opportunities that can accelerate top-line growth and expand profit margins[56] - In 2025, typical rate increases for renewed home health and hospice contracts ranged from 3-5%[101] - Medicaid payments represented only 0.8% of the company's consolidated net service revenue for the year ended December 31, 2025[102] Regulatory Environment and Compliance - The IMPACT Act requires post-acute care providers to report standardized patient assessment data, impacting Medicare-certified hospices[132] - The Review Choice Demonstration (RCD) for home health services was extended for an additional five years in six states, requiring additional administrative costs[134] - The federal government has increased enforcement priorities under the False Claims Act, impacting healthcare providers' compliance requirements[115] - Compliance with extensive laws and regulations is crucial, as failure to comply could result in penalties and significant operational changes[181] - The company is subject to audits that may extrapolate billing errors, potentially leading to larger alleged overpayments[163] Quality of Care and Patient Outcomes - The company achieved a 30-day hospital readmission rate of 14.4% in 2025, which is 20.0% lower than the national average of 18.0%[43] - The percentage of hospice patients receiving in-person visits from registered nurses or medical social workers on at least two out of the final three days of life was 63.8% in 2025, 32.1% higher than the national average of 48.3%[44] - Quality of care reporting requirements are becoming increasingly important, with Medicare imposing financial penalties for excessive patient readmissions and performance metrics impacting reimbursement rates[198] - Home health agencies may face a 2% penalty for failing to meet quality reporting requirements, while hospices could see a 4% penalty, affecting overall reimbursement[199] Staffing and Human Capital Management - The company employed approximately 10,800 individuals as of December 31, 2025, with no employees represented by a labor union[136] - The human capital management strategy in 2025 focused on increasing net full-time nursing and therapy headcount to support Home Health and Hospice growth[138] - The company aims to maintain competitive compensation and benefit programs to attract and retain employees, enhancing employee performance recognition[139] - Employee development initiatives include investments in technology for on-demand learning and succession planning for key positions[141] - The company has implemented a total rewards program that combines pay and benefits with a supportive work culture[139] Market Trends and Industry Challenges - The home health and hospice industries are projected to grow significantly, with Medicare spending for hospice care increasing from $3.0 billion in 2000 to $25.7 billion in 2023, reflecting a compound annual growth rate of 9.8%[26] - The Medicare Advantage enrollment among eligible beneficiaries grew from 19% in 2007 to 54% in 2025, with projections indicating it will rise to 64% by 2034, influencing demand for home health services[31] - The shift towards Medicare Advantage plans may adversely affect net service revenue due to lower reimbursement rates compared to traditional Medicare[156] - Rising staffing costs due to competition for qualified personnel may not be offset by reimbursement rate increases, adversely affecting profitability[211] - The company is facing operational and financial risks due to potential downturns in the economy and increased inflation, which could adversely affect its business and financial statements[190] Merger and Acquisition Activities - The proposed merger with Kinderhook is valued at approximately $1.1 billion and is subject to various closing conditions, including stockholder approval and regulatory consents[144] - If the merger is not completed, stockholders will not receive any payment for their shares, and the company will remain publicly traded on the New York Stock Exchange[147] - The company has incurred significant costs related to the merger, including legal and advisory fees, which may not yield benefits if the merger does not proceed[151] - The merger agreement includes a termination fee of approximately $24.5 million under certain circumstances[149] - The company must comply with operating covenants during the merger period, which may limit its operational flexibility[146] Financial Risks and Challenges - The billing and collection of accounts receivable is complex and may lead to financial reporting issues or liquidity problems due to delays in reimbursement[164] - The company may experience delays in reimbursement from non-governmental payers due to internal challenges, impacting financial reporting and liquidity[171] - The ongoing evolution of healthcare delivery systems and alternative payment models may significantly affect the company's business and results of operations[172] - Changes in Medicaid eligibility requirements may impact net service revenue and the structure of the Medicaid program at the state level[179] - The company is subject to litigation risks inherent in the healthcare industry, which could result in significant costs and adversely affect its financial position[214]

Exhibit 99.1 Enhabit Reports Fourth Quarter 2025 Financial Results DALLAS, TX – March 4, 2026 – Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended Dec. 31, 2025. "Our fourth quarter 2025 results capped a pivotal year for Enhabit, delivering an emerging growth story with year over year increases in patient census, revenue and Adjusted EBITDA," said Barb Jacobsmeyer, CEO and president of Enhabit. "The consistent ex ...

Core Viewpoint - Enhabit (EHAB) reported quarterly earnings of $0.14 per share, matching the Zacks Consensus Estimate, and showing a significant increase from $0.04 per share a year ago, indicating a positive earnings surprise of +3.70% [1] Financial Performance - Enhabit achieved revenues of $270.4 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.40%, and up from $258.2 million in the same quarter last year [2] - The company has exceeded consensus EPS estimates in all four of the last quarters [2] Stock Performance - Enhabit shares have increased approximately 47.5% since the beginning of the year, contrasting with a 0.4% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $264.97 million, and for the current fiscal year, it is $0.56 on revenues of $1.09 billion [7] - The trend of estimate revisions for Enhabit was favorable prior to the earnings release, suggesting potential for continued positive performance [6] Industry Context - The Medical Services industry, to which Enhabit belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Fourth Quarter 2025 Supplemental Information March 4, 2026 Disclaimers Forward looking statements This presentation contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments ...

Core Viewpoint - Monteverde & Associates PC is investigating Enhabit Inc. (NYSE: EHAB) regarding its proposed sale to Kinderhook Industries, LLC, where shareholders are expected to receive $13.80 per share in cash, raising questions about the fairness of the deal [1] Company Summary - Enhabit Inc. is involved in a transaction where it will be sold to Kinderhook Industries, LLC, with shareholders set to receive $13.80 per share [1] - The investigation by Monteverde & Associates PC aims to determine if the sale terms are fair for Enhabit shareholders [1] Legal Context - Monteverde & Associates PC is recognized as a leading firm in class action securities, having recovered millions for shareholders and being listed in the Top 50 Firms in the 2024 ISS Securities Class Action Services Report [1] - The firm operates from the Empire State Building in New York City and has a successful track record in litigation, including cases in the U.S. Supreme Court [1]

Core Viewpoint - The law firm Brodsky & Smith is investigating potential claims against the Board of Directors of Enhabit, Inc. for possible breaches of fiduciary duty related to the sale of the Company to Kinderhook Industries for $13.80 per share, totaling an enterprise value of approximately $1.1 billion [1][2]. Group 1 - The investigation focuses on whether the Enhabit Board breached its fiduciary duties to shareholders by failing to conduct a fair process [2]. - The deal consideration of $13.80 per share is under scrutiny to determine if it provides fair value to the Company's shareholders [2]. Group 2 - Brodsky & Smith is a litigation law firm with expertise in representing shareholders in securities and class action lawsuits, having successfully recovered millions for clients [3].

Core Viewpoint - Enhabit, Inc. is in focus due to a proposed sale to Kinderhook Industries, LLC, with UBS setting a price target of $13.80, slightly above the current trading price of $13.60, indicating a stable outlook for the stock [1][5] Group 1: Proposed Sale and Market Reaction - The proposed transaction involves Enhabit shareholders receiving $13.80 per share in cash, aligning with UBS's price target, suggesting the market has factored in the potential sale price [2] - EHAB's stock price has surged by 22.63%, or $2.51, reflecting investor optimism likely driven by the proposed sale [3][5] - The stock's price today has ranged from $13.55 to $13.64, with the latter being its highest in the past year, indicating strong market interest [3] Group 2: Market Capitalization and Trading Activity - The market capitalization of EHAB is approximately $689.4 million, reflecting the company's overall value in the stock market [4] - With a trading volume of 12.6 million shares, there is significant activity and interest in EHAB, likely influenced by the ongoing investigation and the proposed sale [4]

Core Viewpoint - Enhabit, Inc. is undergoing a significant acquisition by Kinderhook Industries, valued at approximately $1.1 billion, which is expected to enhance its market position and benefit stakeholders [2][4]. Company Overview - Enhabit, Inc. is a leading provider of home health and hospice services in the United States, known for its comprehensive care solutions [1]. Acquisition Details - UBS downgraded Enhabit’s stock rating to Neutral from Hold as the company enters a definitive acquisition agreement with Kinderhook Industries [2][5]. - Stockholders of Enhabit will receive $13.80 per share in cash as part of the acquisition agreement, which includes a premium over the current stock price of $13.60 [3][5]. - The acquisition is an all-cash transaction valued at approximately $1.1 billion [2]. Stock Performance - Enhabit’s stock has increased by 22.63%, reflecting investor optimism regarding the acquisition, with a rise of $2.51 [3][5]. - The stock price has fluctuated between $13.55 and $13.64, with $13.64 being the highest price over the past year [3]. - The market capitalization of Enhabit is approximately $689.4 million, with a trading volume of 12.6 million shares [4].